{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-25-000123","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.882965+00:00","generated_at":"2026-05-16T20:22:37.176351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elicio Q3 net loss $10.1M ($0.60/sh); Phase 2 DFS analysis pushed to 1H 2026 on fewer events","bullets":["Phase 2 AMPLIFY-7P: fewer disease progressions/deaths than projected; event-driven primary DFS analysis now expected 1H 2026.","Raised ~$11.1M gross via ATM since Q3 start; cash $20.6M at Sep 30, extending runway through Q2 2026.","Q3 net loss $10.1M ($0.60/sh) vs $18.8M ($1.39) YoY; R&D expense down to $5.0M from $7.2M.","IDMC recommended continue Phase 2 without modifications; after DFS analysis, will request End of Phase 2 FDA meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-25-000123","json":"https://secwatch.observer/filing/0001601485-25-000123.json","markdown":"https://secwatch.observer/filing/0001601485-25-000123.md","text":"https://secwatch.observer/filing/0001601485-25-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/0001601485-25-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/angn-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:22:37.176351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}